Targacept
CompanyUnited States
Targacept develops one asset, in phase 2, no development reported (ispronicline in Alzheimer's disease). Mostly small molecule acting on CHRNA4 and CHRNB2; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2, no development reported
- 2
- Trials
- 0
- Signals
Pipeline
1Neuronal nicotinic acetylcholine receptor (alpha4beta2) agonist designed to enhance cognitive function.
Phase 2, no development reported, Small molecule, CHRNA4, CHRNB2, Alzheimer's disease, attention deficit hyperactivity disorder
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials3
- Similar companies6